U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170475) titled 'A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease' on Sept. 07.
Brief Summary: This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:
Who can join: Adults with early-stage Parkinson's disease on stable medication regimens.
What participants do:
* Take their assigned dose twice daily (morning and evening) for 12 weeks.
* Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, a...